Compare Adaptive Biotechnologies Corp (ADPT) vs HCA Health Inc (HCA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs HCA Health Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while HCA Health Inc trades at $410.61 (market cap $93.86B). The key difference: HCA Health Inc is far larger — about 28.2× Adaptive Biotechnologies Corp's market cap, and HCA Health Inc pays a 0.74% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | HCA | |
|---|---|---|
Market Cap | $3.33B | $93.86B |
Sector | Health | Health |
52-Week High | $22.37 | $545.13 |
52-Week Low | $10.24 | $334.32 |
Enterprise Value | $3.19B | $142.77B |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
HCA Healthcare trades at $423.11, up 3.07% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with revenue growth to $75.6B in 2025 and consistent earnings beats. Recent news highlights capacity expansion and gene therapy advancements. Technical indicators suggest bullish trends, though RSI signals potential overbought conditions near-term.
Outlook remains positive given earnings momentum and strategic investments, but risks include high debt levels and healthcare regulatory pressures. Analyst consensus targets $493 with 65% buy ratings, indicating upside potential from current levels amid manageable execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
